盤中異動 | 藥明康德盤中下跌7%,報於97.8港元
2022年6月13日9時30分,藥明康德(HK02359)盤中下跌7%,報於97.8港元,成交額達2390.02萬港元,換手率達到0.04%。
6月13日訊,藥明康德(02359.HK)公佈,擬議股東因應資金需求,計劃自7月4日至9月30日期間,按市場價格,通過競價及大宗交易減持合共不超過8,868.03萬股A股,佔股份總數不超過3%。
4月27日,招商證券(香港):維持藥明康德(02359)“買入”評級,目標價250港元。4月27日,裏昂:維持藥明康德(02359)“買入”評級,目標價降至154港元。4月27日,瑞銀:重申藥明康德(02359)“買入”評級,目標價降至173港元。
最新的財務數據顯示,公司於2022年1季度,營業收入84.74億人民幣,淨利潤16.56億人民幣;營業收入同比增加71.18%,毛利潤同比增加65.15%,淨利潤同比增加9.88%。
盈立趨勢長盈模型最近一次交易信號,2022年6月7日出現關注信號,觸發價格爲102.1港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.